Meeting
2020 Genitourinary Cancers Symposium
Treatment response comparisons between ATM and BRCA2 germline carriers for mCRPC.
Authors
Alexandra Sokolova
University of Washington, Seattle, WA
Alexandra Sokolova , Catherine Handy Marshall , Rebeca Lozano , Petros Grivas , Celestia S. Higano , Tamara L. Lotan , Robert B. Montgomery , Peter Nelson , David Olmos , Michael Thomas Schweizer , Todd Yezefski , Evan Y. Yu , Channing Judith Paller , Elena Castro , Emmanuel S. Antonarakis , Heather H. Cheng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Prevention, Screening, and Hereditary Cancers
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 63)
Abstract #
63
Poster Bd #
C7
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Alliance A031902 (CASPAR): A randomized phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).
First Author: Arpit Rao
Poster
2020 Genitourinary Cancers Symposium
Targeting resistant prostate cancer with ATR and PARP inhibition (TRAP trial): A phase II study.
First Author: Zachery R. Reichert
Poster
2019 Genitourinary Cancers Symposium
Response to PARP inhibitor therapy in metastatic castrate-resistant prostate cancer (mCRPC) patients with BRCA1/2 versus ATM mutations.
First Author: Catherine Handy Marshall
Poster
2018 Genitourinary Cancers Symposium
TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician’s choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).
First Author: Charles J. Ryan